Generating a panel of highly specific antibodies to 20 human SH2 domains by phage displayShow others and affiliations
2010 (English)In: Protein Engineering Design & Selection, ISSN 1741-0126, E-ISSN 1741-0134, Vol. 23, no 4, p. 279-288Article in journal (Refereed) Published
Abstract [en]
To demonstrate the utility of phage display in generating highly specific antibodies, affinity selections were conducted on 20 related Src Homology 2 (SH2) domains (ABL1, ABL2, BTK, BCAR3, CRK, FYN, GRB2, GRAP2, LYN, LCK, NCK1, PTPN11 C, PIK3R1 C, PLC gamma 1 C, RASA1 C, SHC1, SH2D1A, SYK N, VAV1 and the tandem domains of ZAP70). The domains were expressed in Escherichia coli, purified and used in affinity selection experiments. In total, 1292/3800 of the resultant antibodies were shown to bind the target antigen. Of the 695 further evaluated in specificity ELISAs against all 20 SH2 domains, 379 antibodies were identified with unique specificity (i.e. monospecific). Sequence analysis revealed that there were at least 150 different clones with 1-19 different antibodies/antigen. This includes antibodies that distinguish between ABL1 and ABL2, despite their 89% sequence identity. Specificity was confirmed for many on protein arrays fabricated with 432 different proteins. Thus, even though the SH2 domains share a common three-dimensional structure and 20-89% identity at the primary structure level, we were able to isolate antibodies with exquisite specificity within this family of structurally related domains.
Place, publisher, year, edition, pages
Oxford University Press (OUP) , 2010. Vol. 23, no 4, p. 279-288
Keywords [en]
ELISA, monospecificity, protein microarray, scFv, time-resolved fluorescence
National Category
Biochemistry Molecular Biology
Identifiers
URN: urn:nbn:se:kth:diva-28304DOI: 10.1093/protein/gzq003ISI: 000276543600016PubMedID: 20164216Scopus ID: 2-s2.0-77953915226OAI: oai:DiVA.org:kth-28304DiVA, id: diva2:386742
Funder
Knut and Alice Wallenberg Foundation
Note
QC 20211215
2011-01-132011-01-122025-02-20Bibliographically approved